Cardiovascular Disease

LUF6096 (Standard) is the analytical standard of LUF6096 (HY-10915). This product is intended for research and analytical applications. LUF6096, a potent allosteric enhancer of the adenosine A3 receptor, is able to allosterically enhance agonist binding. LUF6096 shows low orthosteric affinity for any of the adenosine receptors. LUF6096 shows protective effects in myocardial ischemia/reperfusion injury.

NF449 is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 is a G_sα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s.

Asundexian-d₃ (BAY-2433334-d₃) is the deuterium labeled Asundexian (HY-137431). Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC₅₀ of 1 nM.

Conivaptan (YM 087 free base) is an orally active dual vasopressin V_1a/V₂ receptor antagonist with K_i values of 0.48 nM and 3.04 nM for vasopressin V_1a receptor and V₂ receptor, respectively. Conivaptan competitively and reversibly blocks vasopressin-mediated antidiuresis, vasoconstriction, and cellular hypertrophy, while inhibiting CYP3A4. Conivaptan inhibits vasopressin-induced intracellular calcium, cAMP, and mitogen-activated kinase activation in vascular smooth muscle cells and cardiomyocytes. Conivaptan induces water diuresis while improving hemodynamics in heart failure models, reducing left ventricular end-diastolic pressure, vascular resistance, and organ weight. Conivaptan is used for research on hyponatremia and congestive heart failure.

AD-9308 is an orally active, highly selective aldehyde dehydrogenase 2 (ALDH2) activator. AD-9308 alleviates oxidative stress, improves mitochondrial function, restores cell viability, reduces renal tubular injury, fibrosis and inflammatory responses, reverses ventricular remodeling, restores the activities of Dicer and superoxide dismutase, inhibits the IL-6 signaling pathway, reduces the accumulation of 4-HNE-protein adducts, and improves glucose homeostasis. AD-9308 can be used in studies related to acrolein-induced kidney injury, diabetes, cardiomyopathy, heart failure, diet-induced obesity, fatty liver, insulin resistance and glucose intolerance.

VPC 32183 (ammonium) is a phosphatidic acid.

Dopropidil hydrochloride is a novel anti-anginal calcium ion modulating agent, possessing intracellular calcium antagonist activity and anti-ischemic effects in several predictive animal models.

Orforglipron (Standard) is the analytical standard of Orforglipron (HY-112185). This product is intended for research and analytical applications. Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete.

Quininic acid (Standard) is the analytical standard of Quininic acid (HY-N7354). This product is intended for research and analytical applications. Quininic acid, purified from Eucalyptus globulus, cinchona bark, and other plant products, is the most abundant organic acid.

BAY-549 (Standard) is the analytical standard of BAY-549 (HY-10319). This product is intended for research and analytical applications. BAY-549 (Azaindole 1), a chemical probe, is an orally active and ATP-competitive ROCK inhibitor with IC₅₀s of 0.6 and 1.1 nM for human ROCK-1 and ROCK-2, respectively.

Almitrine mesylate (Standard) (Almitrine bismesylate (Standard)) is the analytical standard of Almitrine mesylate (HY-107319). This product is intended for research and analytical applications. Almitrine mesylate, a peripheral chemoreceptor agonist, inhibits selectively the Ca2+-dependent K+ channel.

DL-Arginine-d₇ hydrochloride is deuterium labeled DL-Arginine hydrochloride (HY-W014375). DL-Arginine ((±)-Arginine) hydrochloride is the racemic compound of L-Arginine (HY-N0455) and D-Arginine (HY-W016781). Arginine is an essential amino acid that requires additional supplementation in traumatic or diseased conditions. Arginine is involved in T cell activation, proliferation, and differentiation, and affects the function of immune cells.

PaPE-1 is a pathway-preferential estrogen receptor (ER) agonist that preferentially activates ER non-nuclear-initiated signaling while minimally activating nuclear-initiated signaling. PaPE-1 exhibits K_i values of 10 μM and 25 μM for human ERα and ERβ, respectively. The relatively low ER affinity and rapid receptor dissociation of PaPE-1 facilitate the triggering of non-nuclear mTOR/MAPK/AKT signaling, while reducing the recruitment of ERα to chromatin and sustained nuclear ER-dependent transcription. PaPE-1 is suitable for research related to non-nuclear ER signaling, metabolic disorders, ischemic brain injury, Alzheimer's disease, and ER-positive breast cancer.

AT2 receptor ligand-1(compound 14) is a potent angiotensin AT2 receptor ligand with the K_i 4.9 nM. AT2 receptor ligand-1 shows high stability in microsomes of the sulfonamide ligands.